Table 1 Clinical features of patients with PD-L1+ and PD-L1− anaplastic large cell lymphoma
ALK+ ALCL (n = 45) | ALK− ALCL (n = 50) | |||||
|---|---|---|---|---|---|---|
PD-L1+a (n = 34) | PD-L1− (n = 11) | P valueb | PD-L1+a (n = 21) | PD-L1− (n = 29) | P valuec | |
Male:female | 1.3:1 (19/15) | 2.7:1 (8/3) | 0.48 | 3.2:1 (16/5) | 2.2:1 (20/9) | 0.75 |
Median age (yrs, range) | 36 (11–58) | 29 (11–67) | 0.61 | 64 (43–95) | 58 (21–77) | 0.09 |
B symptoms | 59% (13/22) | 44% (4/9) | 0.69 | 69% (11/16) | 57% (12/21) | 0.52 |
Nodal presentation | 79% (23/29) | 89% (8/9) | 1 | 72% (13/18) | 74% (20/27) | 1 |
Extranodal involvement | 68% (19/28) | 36% (4/11) | 0.14 | 78% (14/18) | 65% (15/23) | 0.5 |
Bone marrow involvement | 21% (5/24) | 0% (0/10) | 0.29 | 22% (4/18) | 17% (4/23) | 0.71 |
Stage III or IV | 75% (18/24) | 50% (5/10) | 0.23 | 56% (9/16) | 81% (17/21) | 0.15 |
Elevated WBC | 28% (5/18) | 25% (1/4) | 1 | 45% (5/11) | 14% (2/14) | 0.18 |
Absolute lymphocytosis | 0% (0/17) | 0% (0/3) | 1 | 0% (0/11) | 0% (0/13) | 1 |
Elevated serum LDH | 50% (9/18) | 50% (2/4) | 1 | 60% (6/10) | 67% (8/12) | 1 |
IPI ≥ 3 | 17% (3/18) | 13% (1/8) | 1 | 53% (8/15) | 44% (7/16) | 0.72 |
Initial treatment | ||||||
CHOP or modified CHOP | 71% (17/24) | 80% (8/10) | 0.69 | 86% (12/14) | 83% (19/23) | 1 |
Other | 29% (7/24) | 20% (2/10) | 14% (2/14) | 17% (4/23) | ||
Initial CR | 79% (19/24) | 90% (9/10) | 0.64 | 29% (4/14) | 61% (14/23) | 0.09 |
With SCT | 29% (7/24) | 60% (6/10) | 0.13 | 14% (2/14) | 26% (6/23) | 0.68 |
